France's Abivax Looks A Likely M&A Target
ABX464 Could Be IBD Gamechanger
With a candidate for ulcerative colitis set to go into Phase III soon with a safety profile that looks cleaner than anti-TNFs and the JAK class, the French biotech could soon be getting some interesting offers.
You may also be interested in...
Licensing deals and partnerships carried the day during another hectic J.P. Morgan Healthcare Conference. Pfizer racked up its third deal of the week in a cancer collaboration with Dren Bio.
The deal is a nod for Arena's turnaround strategy and could be the start of an active deal-making period for Pfizer, flush with cash.
New Zymeworks CEO Ken Galbraith is laying off at least 25% of the company's staff, including 50% of the senior management team, as the firm looks to advance pivotal trials of its HER2-targeted bispecific antibody zanidatamab.